Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Medication is not a quick fix for obesity, Dr. Samuel L. Wilcox said during a "Lunch & Learn" session at the Iola Public ...

Gov. Jeff Landry struck language from the Louisiana budget plan that could have provided state employees and public school teachers with insurance coverage for popular weight-loss medication over the ...

As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants to bring them back.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...